Prontline Biopharma筹集了60万澳元用于推进癌症药物,在早期人类试验以及中国和美国的新伙伴关系中,他是一个关键候选者。 Phrontline Biopharma raised $60M to advance cancer drugs, with a key candidate in early human trials and new partnerships in China and the U.S.

以中国为基地的一家生物技术公司Prontline Biopharma筹集了6 000万美元A+前资金,以推进其下一代双倍和双荷载抗体药物共产物(ADCs)。 Phrontline Biopharma, a China-based biotech firm, raised $60 million in Pre-A+ funding to advance its next-generation bispecific and dual-payload antibody-drug conjugates (ADCs). 在Lapam投资公司的领导下,三星风险投资公司和其他投资者参加了这轮投资。 Led by Lapam Investment, the round included participation from Samsung Venture Investment Corporation and other investors. 该公司的主要候选人TJ101正在中国和美国接受人类先期试验,其目标为EGFR和B7-H3难以治疗的癌症。 The company’s lead candidate, TJ101, is in first-in-human trials in China and the U.S. and targets EGFR and B7-H3 for hard-to-treat cancers. 2025年10月,Phrontline宣布与Samsung Bioepis开展全球合作,共同开发两个ADC,并与中国内地和香港TJ101的中华生物制药公司签订独家许可证交易。 In October 2025, Phrontline announced a global collaboration with Samsung Bioepis to co-develop two ADCs and an exclusive license deal with Sino Biopharmaceutical for TJ101 in Mainland China and Hong Kong. Samsung的投资支持其通过国际伙伴关系扩大ADC能力的战略。 Samsung’s investment supports its strategy to expand its ADC capabilities through international partnerships.